Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Larisa V. Gubareva"'
Autor:
Larisa V. Gubareva, Juan A. De La Cruz, Anton Chesnokov, Mira C. Patel, Ha T. Nguyen, Lori Lollis, Vasiliy P. Mishin, David E. Wentworth, Vivien G. Dugan
Publikováno v:
J Infect Dis
Susceptibility of influenza A viruses to baloxavir can be affected by changes at amino acid residue 38 in the polymerase acidic (PA) protein. Information on replicative fitness of PA-I38-substituted viruses remains sparse. We demonstrated that substi
Autor:
Vasiliy P, Mishin, Mira C, Patel, Anton, Chesnokov, Juan, De La Cruz, Ha T, Nguyen, Lori, Lollis, Erin, Hodges, Yunho, Jang, John, Barnes, Timothy, Uyeki, Charles T, Davis, David E, Wentworth, Larisa V, Gubareva
Publikováno v:
Emerging Infectious Diseases
Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2–98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses
Autor:
Malania M. Wilson, John Barnes, Larisa V. Gubareva, Juan A. De La Cruz, Rebecca Kondor, David E. Wentworth, Anton Chesnokov, Mira C. Patel, Vasiliy P. Mishin, Ha T. Nguyen
Publikováno v:
Antiviral Research
Baloxavir, a new antiviral drug targeting cap-dependent endonuclease activity of polymerase acidic (PA) protein of influenza viruses, is now approved in multiple countries. Several substitutions at isoleucine 38 in PA protein (e.g., PA-I38T) have bee
Autor:
Larisa V. Gubareva, Katrina Sleeman, Amanda Balish, Vasiliy P. Mishin, Rebecca Garten, Alicia M. Fry, Julie Villanueva, Zhu Guo, James Stevens
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:2045-2051
Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not
Autor:
James Stevens, Vasiliy P. Mishin, Paul J. Carney, Katrina Sleeman, Larisa V. Gubareva, Marnie Levine
Publikováno v:
Antiviral Research. 101:93-96
Propagation of influenza A(H3N2) viruses in MDCK cells has been associated with the emergence of neuraminidase (NA) variants carrying a change at residue 151. In this study, the pyrosequencing assay revealed that ∼90% of A(H3N2) virus isolates anal
Autor:
Jianzhu Chen, Alexander M. Klibanov, Larisa V. Gubareva, Terrence M. Tumpey, Luis Álvarez de Cienfuegos, Alisha K. Weight, Jayanta Haldar
Publikováno v:
PMC
Effects of the commercial drug zanamivir (Relenza™) covalently attached to poly-l-glutamine on the infectivity of influenza A viruses are examined using the plaque reduction assay and binding affinity to viral neuraminidase (NA). These multivalent
Autor:
Michael W. Shaw, Rebecca Garten, Larisa V. Gubareva, Alexander Klimov, Margaret Okomo-Adhiambo, Vasiliy P. Mishin, Tiffany G. Sheu, Varough M. Deyde, Ha T. Nguyen, A. Angelica Trujillo, Alicia M. Fry, Katrina Sleeman
Publikováno v:
Antiviral Therapy. 15:1151-1159
Background Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the drug susceptibility of 2009 pandemic influenza A (H1N1) viruses collected globally between April 2009 and January 2010. Me
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:3671-3677
The neuraminidase inhibitors (NAIs) zanamivir and oseltamivir are currently the only antiviral drugs effective for the treatment and prophylaxis of 2009 pandemic influenza A (H1N1) virus infections. The proven potential of these viruses to acquire NA
Autor:
Rebecca Garten, Ha T. Nguyen, Tiffany G. Sheu, Varough M. Deyde, Alexander Klimov, Katrina Sleeman, Margaret Okomo-Adhiambo, Xiyan Xu, Michael W. Shaw, Larisa V. Gubareva
Publikováno v:
Antiviral Research. 85:381-388
The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are essential for treatment and prevention of influenza A and B infections. Oseltamivir resistance among influenza A (H1N1) viruses rapidly emerged and spread globally during the 2007-20
Autor:
Jianzhu Chen, Larisa V. Gubareva, Luis Álvarez de Cienfuegos, Jayanta Haldar, Terrence M. Tumpey, Alexander M. Klibanov
Publikováno v:
PMC
Alex Klibanov
Alex Klibanov
Purpose: New antiviral agents were prepared by attaching derivatives of sialic acid (1) and of the drug zanamivir (2) to poly(isobutylene-alt-maleic anhydride) (poly-(1 + 2)) or by mixing poly-1 and poly-2, followed by assaying them against wild-type